Licensed weight-management medicines currently available in the UK include: Semaglutide (Wegovy) approved by the MHRA for chronic weight management in adults with a BMI of 30 kg/m or above, or 27 kg/m or above with at least one weight-related comorbidity
Short peptides are distinctive biomolecules that combine the benefits of traditional small molecules and mature proteins, offering new, more effective therapeutic agents with fewer side effects (Apostolopoulos et al., 2021
Practical guidelines for the management of toxic epidermal necrolysis and StevensJohnson syndrome
For top-end speed and performance, 120C LiPo batteries are ideal
During treatment, periodic follow-up matters more than many people expect
While ongoing monitoring of calcitonin during GLP-1 therapy is not standard practice, patients should receive education about thyroid cancer warning signs and the importance of reporting new symptoms